AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Jasper Therapeutics shares surge 22.11% after-hours after reporting positive ETESIAN study data and resolving BEACON study issues.
ByAinvest
Tuesday, Dec 2, 2025 4:01 pm ET1min read
Jasper Therapeutics surged 22.11% in after-hours trading following the release of positive preliminary data from its ETESIAN Phase 1b/2a study of briquilimab in asthma and the resolution of concerns from its BEACON study. The ETESIAN results showed significant reductions in airway hyperresponsiveness, eosinophilic inflammation, and serum tryptase after a single 180mg dose of briquilimab, supporting its potential as a novel asthma treatment. Additionally, Jasper concluded its BEACON study investigation, confirming no drug-product issues and attributing prior underperformance to patient selection errors. The favorable safety profile of briquilimab and the study’s proof-of-concept for mast cell depletion in asthma reinforced investor optimism about its therapeutic potential. The company’s upcoming conference call to discuss findings further amplified market reaction.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet